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Abstract
The kidneys and the urinary tract are a common source of infection in children of all ages, especially infants and young
children. The main risk factors for sequelae after urinary tract infections (UTI) are congenital anomalies of the kidney
and urinary tract (CAKUT) and bladder-bowel dysfunction. UTI should be considered in every child with fever without
a source. The differentiation between upper and lower UTI is crucial for appropriate management. Method of urine
collection should be based on age and risk factors. The diagnosis of UTI requires urine analysis and significant growth
of a pathogen in culture. Treatment of UTI should be based on practical considerations regarding age and presentation
with adjustment of the initial antimicrobial treatment according to antimicrobial sensitivity testing. All children, regard-
less of age, should have an ultrasound of the urinary tract performed after pyelonephritis. In general, antibiotic prophy-
laxis is not recommended.
Conclusion: Based on recent data and in line with international guidelines, multidisciplinary Swiss consensus recommenda-
tions were developed by members of Swiss pediatric infectious diseases, nephrology, and urology societies giving the clinician
clear recommendations in regard to diagnosis, type and duration of therapy, antimicrobial treatment options, indication for
imaging, and antibiotic prophylaxis.
What is Known:
• Urinary tract infections (UTI) are a common and important clinical problem in childhood. Although children with pyelonephritis tend to present with
fever, it can be difficult on clinical grounds to distinguish cystitis from pyelonephritis, particularly in young children less than 2 years of age.
•Method of urine collection is based on age and risk factors. The diagnosis of UTI requires urine analysis and significant growth of a pathogen in culture.
What is New:
• Vesicoureteric reflux (VUR) remains a risk factor for UTI but per se is neither necessary nor sufficient for the development of renal scars. Congenital
anomalies of the kidney and urinary tract (CAKUT) and bladder-bowel dysfunction play a more important role as causes of long-term sequelae. In
general, antibiotic prophylaxis is not recommended.
• A switch to oral antibiotics should be considered already in young infants. Indications for invasive imaging are more restrictive and reserved for
patients with abnormal renal ultrasound, complicated UTI, and infections with pathogens other than E. coli.
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ASB Asymptomatic bacteriuria
AST Antimicrobial sensitivity testing
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MSU Midstream urine
PCT Procalcitonin
UTI Urinary tract infection
VUR Vesicoureteric reflux
Introduction
The kidneys and the urinary tract are a common source of
infection in children of all ages, especially infants and young
children. Acute upper urinary tract infections (UTIs; pyelone-
phritis) may lead to substantial morbidity [1–3]. UTIs per se
are only responsible for a small extent for future morbidity,
e.g., arterial hypertension or chronic kidney disease [4]. The
main risk factor for these sequelae is congenital anomalies of
the kidney and urinary tract (CAKUT) [5]. The last Swiss
consensus recommendations on UTI were published in 2013
[6]. Based on recent data and in line with international guide-
lines [7, 8], the Swiss recommendations have now been up-
dated in regard to approaches to diagnosis [9–11], type and
duration of antimicrobial treatment [9–14], indications for im-
aging [15, 16], and antibiotic prophylaxis [17–20]. As the age
of the patient at presentation is an important factor regarding
clinical management, specific recommendations are, where
relevant, stratified by age. European guidelines on UTI man-
agement in children were published in 2015 by Stein et al.
[21]. We have therefore aimed to provide up-to-date recom-
mendations for UTI management for Switzerland but also for
anyone who is managing children with UTI.
Methods
The consensus recommendations were developed by mem-
bers of the Swiss Working Group of Paediatric Nephrology
(SAPN), the Pediatric Infectiology Group Switzerland
(PIGS), and the Swiss Society for Paediatric Urology
(SwissPU), who are experts on the management of UTI to
form the recommendations committee.
The following aspects have been the focus of the current
recommendations, giving added value to the clinician looking
after children with suspected or confirmed UTI:
& The method of urine collection, including non-invasive
methods for fast mid-stream urine sampling
& The use of ultrasound (US), voiding cystourethrogram
(VCUG), and additional imaging modalities including
functional MR-urography in the setting of UTI in children
& Age-appropriate indications for parenteral antibacterial
treatment, including the switch to oral and total length of
treatment
& The indications for antibacterial prophylaxis
& The management of risk factors including bowel dysfunc-
tion for UTI and diagnosis thereof
Based on the above aspects, the review of the literature
(publications up to December 2019) was performed on
PubMed, Embase, and Cochrane. The following search terms
were used: UTI, cystitis, pyelonephritis, UTI and/or urine anal-
ysis and culture, catheterization, aspiration, MSU, clean catch,
ultrasound, MRI, VUR, risk, CAKUT, treatment, prophylaxis,
bowel-bladder dysfunction. The online search was filtered for
age “birth to 18 years.” Only articles including newborns and
children up to the age of 16 years were reviewed for the devel-
opment of these recommendations. The following types of
studies were included to answer the clinical questions: random-
ized controlled trials, cohort and case-control studies, and case
series. If available, all of these study types were included. Data
relevant to the clinical questions were extracted from the studies
to answer the questions. Recommendations were then formu-
lated. A consensus decision was adopted when evidence was
low. In these cases, all relevant papers and statements were
discussed by all the authors until a consensus was achieved.
The individual recommendations were graded according to
the level of evidence using the GRADE method [22] defining
the evidence quality (high, moderate, low, or very low) and
including a recommendation grade (weak or strong).
Aim
These recommendations are aimed at health care professionals
working in the hospital or out-patient setting. They give guid-
ance on the optimal management (workup, diagnosis,
treatment, and follow-up) of children with suspected and con-
firmed UTI as first or recurrent event. They are aimed at all
age groups from neonates to adolescents up to 16 years with
and without pre-existing risk factors for the development of
UTI including also children with underlying CAKUT. The
recommendations do not apply to children with known prima-
ry or secondary immunodeficiency or hospital-acquired UTI.
Recommendation no. 1: Clinical suspicion of UTI
UTI should be considered in every child with fever
without source (evidence quality: high; recommendation:
strong)
For the investigation of UTI, a systematic approach is partic-
ularly important in newborns and children under 2 years pre-
senting with fever. This age group commonly lacks typical
clinical signs (see recommendation no. 2). In addition, UTI
in newborns and infants can also be associated with poor
feeding, failure to thrive, lethargy, or irritability, even without
fever. UTI is defined as the presence of clinical signs and
symptoms in combination with pyuria and significant
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bacteriuria. Details and special situations are described in the
following recommendations.
There are a number of pre-existing factors which increase
the risk of developing UTI:
– Congenital anomalies of the kidney and/or urinary tract
(CAKUT), diagnosed antenatally or postnatally
– Family history of vesicoureteric reflux (VUR) or renal
disease
– Uncircumcised male infants
– Abnormal urine flow or dysfunctional voiding
– Constipation
– History suggesting previous UTI or confirmed recurrent
UTI
Recommendation no. 2: Differentiation between
upper and lower UTI
The differentiation between upper (pyelonephritis) and lower
(cystitis) UTI is crucial for appropriate management (evidence
quality: high; recommendation: strong)
The classic clinical signs and symptoms of UTI are
pollakisuria, dysuria, loin tenderness, and fever. Infants and
children who have bacteriuria and fever should be considered
having acute pyelonephritis rather than cystitis. Fever may be
absent in children < 2 years of age while other non-specific
signs and symptoms as specified in recommendation no. 1
may be present. Hence, in children < 2 years of age, the pres-
ence of pyelonephritis should be assumed in case of doubt.
Lower UTI is particularly common in girls > 2 years of age. A
diagnosis of cystitis can be considered in these children when
presenting with dysuria, pollakisuria, and bacteriuria; fever
and loin tenderness, however, are not present (see recommen-
dation no 4). Regarding inflammatory markers to rule in or
rule out pyelonephritis, there is no robust evidence [23].
However, repeatedly low levels of inflammatory markers such
as C-reactive protein (CRP < 20 mg/l) or procalcitonin (PCT
< 0.5 μg/l) make the diagnosis of pyelonephritis less likely
[24]. Ultrasound of the urinary tract is neither able to prove
nor exclude the presence of pyelonephritis.
Recommendation no. 3: Methods of urine collection
In infants and toddlers, bladder catheterization
and suprapubic aspiration are recommended methods
of urine collection and are considered the “gold standard”
for a reliable UTI diagnosis (evidence quality: high;
recommendation: strong)
Bladder catheterization is performed more frequently than
suprapubic aspiration. It is considered safe, and the risk of
causing an infection is low. As the catheterization of males
can be difficult, it should be performed or supervised by an
experienced health care professional. When considering either
of these methods, pre-interventional ultrasound guidance is
helpful in assessing the presence of urine in the bladder.
Collection of midstream urine (MSU) is the preferred method
in cooperative children with established bladder control and
following appropriate instruction. A “clean catch” urine sample
represents a valid alternative in infants and younger children.
Here, the mid urine stream is caught by the parents or health
care professional after peri-genital cleaning with sterile water or
normal saline and waiting for the void. Non-invasive stimula-
tion (bladder tapping with or without massage of the sacral
area) trigger faster samples [25, 26]. The method of collection
is an important factor when interpreting results from urine anal-
ysis as MSU and clean catch have a higher contamination rate
compared with catheterization and suprapubic aspiration. Urine
collection bags should be used only for excluding UTI. Urine
from collection bags should not be sent for urine culture as the
urine will usually be contaminated with perineal flora. When a
collection bag is used, it is important to attach it only for a short
time (15–30 min), remove it immediately after voiding, and
analyze the urine without delay. In the case of pathological
findings, a second urine sample should be obtained through
catheterization, clean catch, or suprapubic aspiration and sent
for urine culture before initiation of empiric antibiotic therapy.
An overview of age-specific recommendation for urine collec-
tion is detailed in Table 1.
Recommendation no. 4: Urine analysis and culture,
additional laboratory testing
The diagnosis of UTI requires urine analysis and culture. Urine
dipstick (leukocyte esterase and nitrite) or microscopy alone
is not sufficient to definitively confirm UTI (evidence quality:
high; recommendation: strong)
In the primary care setting, dipstick testing represents a fast
and convenient and sufficient way to perform urine analysis.
In this setting, the additional slight gain in sensitivity of mi-
croscopic analysis does not justify the added cost and time. It
should be noted that in a few situations dipstick may be false
negative (for example negative leucocytes and negative nitrite
in children under 3 months of age who have a high voiding
frequency or in infections with Enterococcus spp.) [27].
Dipstick may also be false positive in the context of other
situations (e.g., contamination, fever due to a different cause,
inflammatory processes) [28]. In the hospital laboratory, the
dipstick can be combined with urine microscopy in order to
slightly improve sensitivity. However, the focus here is on the
gain in specificity, especially in young infants, as well as the
extended microscopic assessment of urine with unclear find-
ings on dipstick testing. Even when both tests are used, the
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sensitivity is not 100%, so that a urine culture is essential for a
reliable diagnosis.
Indications for urine culture:
– Always in children ≤ 90 days of age with suspected UTI/
fever without source
Table 1 Summary of UTI management (AST: antimicrobial susceptibility testing)
A. Procedures and investigations
Age Choices Alternative
Urine collection
≤ 90 days Catheterization/clean catch Suprapubic aspiration
> 90 days Clean catch/catheterization Suprapubic aspiration, collection bag (only for exclusion of UTI)
Urine testing and culture
≤ 90 days Urine analysis and Culture
> 90 days Urine analysis Culture if positive dipstick (Leukocyte esterase and/or nitrite) or pyuria on microscopy
Independent of age
Septic patient Urine analysis and culture
Recurrent UTI Urine analysis and consider
culture
Clinical signs and symptoms not correlating with urine analysis results: Culture
Additional laboratory testing (to consider)
≤ 90 days CRP and/or PCT, complete blood count, blood culture, plasma creatinine, sodium (Na), potassium
> 90 days CRP and/or PCT
Independent of age
Septic patient, neonates Full sepsis workup (blood, urine and cerebrospinal fluid
investigations and cultures)
B. Empiric therapy UTI
≤ 30 days 31–60 days From 61 days (> 2 months) From 180 d (6 months)
Fever (> 38 °C)
Pyelonephritis
Amoxicillin +
aminoglycoside IV
Amoxicillin + ceftriaxone IV Oral: amoxicillin-clavulanate or 3rd
gen. cephalosporine
Treatment duration 7–10 days 7–10 days 7–10 days
Route IV
Switch to an oral antibiotic
may be considered in line
with AST:
- If good clinical response,
tolerating oral feeding
- No meningitis
- No sepsis at presentation
- After at least 3 days iv
Start IV and switch to oral
Switch to an oral antibiotic (in
line with AST) if good
clinical response; if sepsis at
presentation consider full
7–10 days iv or may switch
to oral after 3 days iv with
improved general state and
tolerating oral feeding
Oral
Start IV (ceftriaxone) if poor
general condition or unable to
tolerate oral feeding
Afebrile
Cystitis
Oral: trimethoprim-sulfam
ethoxazole or
amoxicillin-clavulanate
Treatment duration 3 days
Route Oral
C. Reassessment after initiation of treatment
All children should be reassessed on days 3 to 5 following UTI diagnosis for (i) clinical (and possibly laboratory) response to treatment, (ii) confirmation
of the diagnosis, and (iii) possibly adaptation of the therapy according to the AST (aim: narrowing antimicrobial spectrum)
Treatment should be ceased if the UTI diagnosis is not confirmed (in case of a negative urine culture).
Repeat urine testing is only needed if no adequate response to treatment is seen (consider complications or other differential diagnoses).
D. Follow-up investigations
All children experiencing a first episode of UTI (excluding afebrile UTI in children > 180 days) should be investigated by ultrasound of the kidneys and urinary
tract within 6 weeks of the diagnosis
MCUG should only be performed in children with any of the following risk factors: CAKUT, abnormal ultrasound suggesting anatomical pathology,
non-E. coli UTI, sepsis, inadequate response to treatment within 48 h, signs of chronic kidney disease (increased creatinine or dyselectrolytemia
(sodium, potassium) or elevated blood pressure), poor urine flow, recurrent (febrile) UTIs
E. Antibacterial prophylaxis
Prophylaxis only to be considered in VUR grades IV and V (WHO grading I–V).
If MCUG is indicated, antibiotic prophylaxis may be started and continued up to the examination.
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– In children > 90 days who are suspected clinically of
having acute pyelonephritis and have a positive dip-
stick (leukocyte esterase/nitrite) and/or urine micros-
copy result (pyuria)
– In all children in a reduced general condition or with a
high suspicion of serious bacterial illness
– In all children with recurrent UTI and underlying conditions
(CAKUT, high-grade VUR (WHO grading IV and V)
– In all children if clinical symptoms and signs do not cor-
relate with dipstick/microscopy analysis
Additional laboratory testing Empiric antibacterial therapy
should only be initiated after obtaining a urine sample for
analysis and culture. In cases where parenteral therapy is in-
dicated, blood cultures should always be obtained in addition
to a urine culture before starting therapy. Particularly in neo-
nates and also in infants in reduced general state, a sepsis
workup (blood, urine, and cerebrospinal fluid investigations
and cultures) should be obtained if possible prior to starting
empiric antibacterial therapy.
An overview of age-specific recommendation for urine
analysis and additional laboratory testing is detailed in
Table 1.
Recommendation no. 5: Definition of a positive urine
culture
In urine obtained through catheterization, the growth
of a single uropathogen of ≥ 10,000 CFU/ml (104) and,
in midstream urine samples, the growth of a single
uropathogen of ≥ 100,000 CFU/ml (105) are highly
suggestive of UTI. (evidence quality: moderate;
recommendation: weak)
In young infants (< 3 months of age) with frequent urination,
growth of 1000–10,000 CFU/ml (103–104) in urine obtained
by catheterization may already be indicative of UTI. In urine
obtained by suprapubic aspiration, any bacterial growth is
usually highly suggestive of UTI. In general, growth of ≥ 2
different bacterial species suggests contamination [8, 29, 30].
However, particularly in young infants, the growth of two
bacterial species (particularly E. coli and Enterococcus) may
be a relevant finding and should be considered to represent a
true UTI if signs and symptoms and additional laboratory
workup are in line with this diagnosis [31, 32]. Significant
growth of so-called non-E.coli bacteria is frequently associat-
ed with the presence of an anatomical malformation
(CAKUT) and should prompt follow-up with imaging in
young children up to the age of 3 years and should also be
considered in older children with incontinence or dysfunction-
al voiding when underlying obstipation has been ruled out
[15] (see also recommendation nos. 1 and 8). In a recent
meta-analysis performed by Coulthard [33] looking at the op-
timal bacterial colony count threshold in urine obtained from
voided or invasive methods, growth of a single uropathogen at
≥ 100,000 CFU/ml (105) had the highest sensitivity (0.99) for
correctly diagnosing UTI independent of age and method
used. On the other hand, urine culture alone should not be
used as a single criterion to make the diagnosis of a UTI but
should always be considered in the context of the clinical
situation (pretest probability, previous history, risk factors,
clinical findings, results from urine analysis, and blood exam-
inations (see also recommendation nos. 1, 2, and 4)) to make
the best possible diagnosis [34].
In rare cases, pyelonephritis may present without pyuria
and/or bacteriuria: in children who present with fever without
source, raised inflammatory markers, flank pain or vomiting,
and normal urine analysis and bacteriology, a MRI or static
isotope nephrogram may be indicated to rule out or prove the
presence of (focal) pyelonephritis [35, 36].
It is not recommended in infants and children to screen for
or treat asymptomatic bacteriuria. Asymptomatic bacteriuria
indicates colonization of the bladder with bacteria, often non-
virulent, without clinical symptoms of UTI and with a normal
urine analysis [37, 38].
Recommendation no. 6: Treatment of UTI
Treatment of UTI (choice of antimicrobial, route
of administration) should be based on age and clinical
presentation, as well as risk factors from the patients’
past medical history. In children < 60 days, consider always
starting with parenteral treatment. In children > 60 days
in good general condition initiating treatment orally
or parenterally is equally efficacious (evidence quality: high;
recommendation: strong). Local antimicrobial sensitivity
patterns (if available) should be considered when choosing
an empirical agent. Adjustment of the initial treatment
should be done according to antimicrobial sensitivity testing
(AST) of the isolated uropathogen (evidence quality: high;
recommendation: strong). The clinician should choose 7
to 10 days as the total duration of antimicrobial therapy
for upper UTI (evidence quality: moderate; recommendation:
weak)
In general, treatment for children with suspected UTI depends
on the age of the child, severity of illness, presence of con-
comitant gastrointestinal symptoms (e.g., vomiting), underly-
ing medical and/or urologic comorbidities, and the local anti-
microbial resistance patterns. As there is an increased inci-
dence of urosepsis in neonates and infants aged less than
2 months, starting with parenteral antibiotic therapy is recom-
mended. There is currently little evidence available to guide
the total duration of antimicrobial therapy in children with
febrile UTIs. However, treating for periods of 7–10 days is
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considered safe also in young children < 90 days [10–12, 39].
This duration is also considered safe, according to recent data,
in parenterally treated infants < 60 days with bacteremic UTI
and ruled out concomitant meningitis [11].
In children with a severe course of UTI and underlying
medical and/or urological comorbidities, one may consider
treating for longer periods.
Switch to oral treatment
There is limited data regarding bioavailability of most oral anti-
biotics in infants below 3 months of age. Clinical and safety data
in the age group < 6 months are however encouraging. A large
retrospective study of infants younger than 6 months (68% were
< 3 months; 19% were neonates) found no difference in treat-
ment failure between intravenous antibiotics for 3 days or less
and 4 days or more [40]. A Cochrane review (birth to 18 years
included) and trial (1 to 36 months included) of acute pyelone-
phritis in children treatedwith 10–14 days of antibiotics found no
difference in the duration of fever or renal damage between all
intravenous antibiotics, 3 days of intravenous followed by oral
antibiotics, or all oral administration [14, 41]. In a retrospective
review of neonates with UTI (bacteremic and non-bacteremic
included) but without meningitis, a median length of 4 days of
parenteral antibiotics followed by oral treatment, no treatment
failure, or relapse was observed [42].
Summary of treatment recommendations of all age
groups
1. Beginwith parenteral antibiotics in children < 60 days and in
children at risk of serious illness or likely unable to take oral
medication (clinically unwell/septic, vomiting, poor
feeding).
2. Once urine culture results and antimicrobial susceptibility
testing are available, a targeted monotherapy is strongly
recommended (antibiotic options and dosages are detailed
in Tables 1 and 2).
3. In the case of a multidrug-resistant pathogen (e.g.,
extended-spectrum beta-lactamase (ESBL) producing
Gram negatives), discuss infection control measures and
treatment with a pediatric infectious disease specialist.
4. Do not switch to oral therapy in the event of an inadequate
response to parenteral therapy, vomiting, or poor feeding.
5. Management of children for whom no standard oral anti-
microbial can be identified, based on antimicrobial sus-
ceptibility testing of the urine culture, should be discussed
with a pediatric infectious disease specialist.
6. In children with acute and/or chronic renal failure, with
severe renal/urological malformations, neurogenic blad-
der, or foreign material, the optimal management strategy
includes initial parenteral route of antibiotic administra-
tion; possible step down to oral medication should be
determined after a multidisciplinary consensus involving
nephrologists, urologists, and infectious disease special-
ists has been reached.
7. In case of sepsis, increasing the duration of parenteral
treatment may be required.
Age-specific recommendations for empiric antibiotic therapy
and duration are detailed in Tables 1 and 2. Options for empiric
oral agents in Switzerland are currently amoxicillin-clavulanate
or 3rd generation cephalosporin. Deciding which of these two
options is the first-line empiric oral agent should be done locally.
AST patterns by pathogen, age, in- vs. out-patient, and area of
living in Switzerland are published online (www.anresis.ch) and
can help with the above decision. Antibiotic dosages and
maximal daily dosages are, where available, in accordance with
SwissPedDose (www.swisspeddose.ch).
Recommendation no. 7: Follow-up during the course
of infection
On days 3 to 5 after initial diagnosis and start of empirical
antibiotic therapy, children should be clinically reviewed
to assess the response to treatment and confirming
the diagnosis. Urine culture results should be reviewed,
and medication adjusted (narrowing the antimicrobial
spectrum) if indicated based on the AST. If there is no
significant growth from urine, the empirical antimicrobial
therapy should be stopped, and an alternative diagnosis
evaluated. (evidence quality: high; recommendation: strong)
A repeated evaluation of the child after day 3 is only necessary if
there are signs of ongoing or worsening infection, i.e., if the child
is still febrile or the clinical condition has not improved. In these
cases, the initial working diagnosis may have to be reconsidered
and other differential diagnoses or complications such as a
pyonephrosis or (peri)renal abscess evaluated. Performance of
an ultrasound of kidneys and urinary tract in these situations is
necessary (Table 1).
Recommendation no 8: The role and timing of urinary
tract imaging in pyelonephritis
All children, regardless of age, should have an ultrasound
of the urinary tract performed after the first episode
of pyelonephritis (evidence quality: moderate;
recommendation: weak). Micturition cystourethrogram
should only be planned under certain circumstances.
(evidence quality: moderate; recommendation: weak)
Ultrasound of the kidneys and urinary tract during the acute
phase can neither rule in nor rule out an upper UTI
(pyelonephritis) or VUR. It may detect anatomical
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malformations or the rare case of pyonephrosis (pus in the
urinary collecting system: pyelon and/or ureter) with second-
ary obstruction. In children with typical upper UTI
(pyelonephritis) responding to treatment, ultrasound, per-
formed in the acute phase, does not influence management.
It is recommended to perform an ultrasound during the acute
infection to identify structural anomalies in the following sit-
uations [8, 43–45]:
– Children presenting with features of atypical upper UTI
(sepsis or septic shock, poor urine flow, abdominal or
bladder mass, increased creatinine, failure to respond to
treatment with suitable antibiotics within 48 h)
– Children presenting with recurrent UTI
If the above features and aspects are not present, ultrasound
can be performed at a later stage after pyelonephritis.
In children with non-E. coli UTI responding well to antibi-
otics and with no other features of atypical infection (as stated
above), the ultrasound can be performed after the acute phase
(Table 1).
Table 2 Treatment and prophylactic antimicrobial options for UTI
Antibiotic Dosage Maximum daily dose Comment
A. Upper UTI (pyelonephritis): oral
Amoxicillin/clavulanate 40 mg/kg/dose 2× daily p.o. 3 g Based on amoxicillin component
Cefpodoxime 4 mg/kg/dose 2× daily p.o. 400 mg Age ≥ 30 days
Cefuroxime 15 mg/kg/dose 2× daily p.o. 1 g
Amoxicillin 40 mg/kg/dose 2× daily p.o. 3 g
B. Upper UTI (pyelonephritis): intravenous
Amoxicillin 25–50 mg/kg/dose 3–4× daily iv. 12 g
Gentamicin 7.5 mg/kg/dose 1× daily i.v./i.m. For neonates and preterms, also consult
neonatal antimicrobial guidelines
Amikacin 15 mg/kg/dose 1× daily i.v./i.m. 1.5 g For neonates and preterms, also consult
neonatal antimicrobial guidelines
Tobramycin 4–6 mg/kg/dose 1× daily i.v./i.m. 7.5 mg/kg For neonates and preterms, also consult
neonatal antimicrobial guidelines
Ceftriaxone 50 mg/kg/dose 1× daily i.v./i.m. 2 g For neonates and preterms, also consult
neonatal antimicrobial guidelines
Cefuroxime 33 mg/kg/dose 3× daily i.v. / i.m. 4.5 g
Amoxicillin/clavulanate 25–50 mg/kg/dose 3–4× daily iv. 12 g Based on amoxicillin component
C. Lower UTI (cystitis): oral
Trimethoprim-sulfamethoxazole 3–5 mg/kg/dose 2× daily p.o. 320 mg Based on trimethoprim; age > 30 days;
contraindicated in hyperbilirubinaemia
Amoxicillin 25 mg/kg/dose 2× daily p.o. 4 g
Amoxicillin/clavulanate 25 mg/kg/dose 2× daily p.o. 4 g Based on amoxicillin
Cefuroxime 10–15 mg/kg/dose 2× daily p.o. 1 g
D. Antibiotic prophylaxis
Trimethoprim 1.5 mg/kg/dose 2× daily or
2 mg/kg/dose 1× daily (evening)
320 mg Neonates and children: twice daily regimen
for children still wearing diapers;
Infectotrimet® suspension can be ordered
by local pharmacy from neighboring
countries. No Swissmedic application
necessary.
Trimethoprim-sulfametoxazole 1 mg/kg/dose 2× daily or
2 mg/kg/dose 1× daily (evening)
320 mg Age > 30 days; dose based on trimethoprim
(TMP); twice daily regimen for children
still wearing diapers.
Nitrofurantoin 1 mg/kg/dose 2× daily or
2 mg/kg/dose 1× daily (evening)
100 mg/dose Age > 30 days
Amoxicillin 10 mg/kg/dose 2× daily Use for prophylaxis only for neonates (if
trimethoprim not available)
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Micturition cystourethrogram
The aim of micturition cystourethrogram (MCUG) is to detect:
– High-grade VUR (WHO grades IV and V)
– Posterior urethral valves (PUV) in boys
– Bladder and ureteric anomalies (for example ureterocele)
We recommend performing MCUG only in the following
circumstances:
– CAKUT and/or dilatation of the urinary tract on ultra-
sound (an isolated mild dilatation of the renal pelvis (≤
10 mm) is not an indication for further imaging)
– Poor urine flow, e.g., posterior urethral valves [PUV] in
boys, oliguria not due to dehydration, urinary retention
– Infection with organisms other than E. coli
– Failure to respond to treatment with suitable antibiotics
within 48 h
– Increased creatinine (according to age) or abnormal electro-
lytes (for example, hyponatremia and hyperkalemia with
suspicion of secondary transient pseudohypoaldosteronism)
or arterial hypertension
– Recurrent pyelonephritis (2 or more episodes)
MCUG should not be performed in the first episode of UTI
in a neonate or young infant as routine examination if above-
listed circumstances are not present [15, 46]. If there is a
family history of VUR (WHO grades IV and V), a MCUG
may be considered on an individual basis. MCUG is indicated
mainly in the setting of UTI for children up to the age of
3 years as it is rare that a child first presents with signs and
symptoms or complications of VUR, PUV, or bladder abnor-
malities at a later age [7]. In older children, bowel-bladder
dysfunction and constipation are more likely responsible for
first and particular recurrent UTI and should therefore be
screened for (see recommendation 10).
Timing of MCUG
If MCUG is indicated after UTI, it may be performed as soon
as available by the local radiology department. The early
timing of MCUG (within 8 days after onset of antimicrobial
therapy) does not influence the detection of VUR as shown in
a recent review [47].
Antibiotic prophylaxis and MCUG
If MCUG is indicated, antibiotic prophylaxis may be started
and continued up to the time of the examination (see Table 2
for options).
Further imaging modalities
If a pediatric radiology department has experience in contrast-
enhanced ultrasound, this method (without exposing the child
to ionizing radiation) can be used as an alternative to MCUG
primarily in girls. In boys, it cannot rule out posterior urethral
valves (PUV). Depending on findings on ultrasound and
MCUG and after interdisciplinary (pediatric nephrology/urol-
ogy) discussion, functional imaging (MR urography, scintig-
raphy) may be performed depending on the local expertise of
the radiology department and availability of pediatric anesthe-
siology support.
Recommendation 9: Indications for long-term antibi-
otic prophylaxis
In general, antibiotic prophylaxis is not recommended
(evidence quality: high; recommendation: strong)
In the following circumstances, antibiotic prophylaxis may be
indicated (planned duration should be documented):
– Children with complex CAKUT or with underlying blad-
der dysfunction (only after interdisciplinary—pediatric
nephrology/urology/infectious diseases—review)
– Children with high-grade VUR (WHO grades IV and V)*
– If MCUG is indicated, antibiotic prophylaxis may be
started and continued until the time of the examination
*In children with VUR grade III, prophylaxis should be
discussed on an individual basis with parents. The number
needed to treat (NNT) for prophylaxis are 5500 antibiotic
doses to prevent one UTI [48]. Antibiotic prophylaxis has
not been shown to reduce renal scarring [17, 18, 49]. Side
effects of antibiotics, contribution to resistance problems
[48], and influence on the intestinal microbiome should also
be considered [50].
There are no evidence-based guidelines on the duration of
antibiotic prophylaxis. The indication should be reviewed af-
ter 6–12 months in correlation with clinical course and imag-
ing follow-up. A second MCUG is generally not recommend-
ed and should always be preceded by an interdisciplinary dis-
cussion by the involved specialists.
Choice of antibiotic for prophylaxis
Trimethoprim (if available as a single substance) is a suitable
prophylactic option in neonates. To prevent the development
of resistance, beta-lactam and quinolone antibiotics should not
be used. Newborns are an exception, where amoxicillin is an
accepted prophylactic agent. The prophylactic antimicrobial
should not be chosen based on the AST of the urine culture. If
two or more UTIs develop under running prophylaxis,
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consider changing prophylaxis to a different agent. Options
and dosages are detailed in Table 2.
Antimicrobial dosages and maximal daily dosages are,
where available, in accordance with SwissPedDose recom-
mendations (www.swisspeddose.ch).
Recommendation 10: Bladder-bowel dysfunction is a
relevant risk factor for recurrent UTI (evidence quali-
ty: high; recommendation: strong)
Lower urinary tract dysfunction, e.g., dysfunctional voiding
during daytime and lack of complete bladder emptying (resid-
ual urine) in combination with bowel dysfunction, e.g., con-
stipation, are labeled as bladder-bowel dysfunction (BBD).
BBD is a relevant risk factor for recurrent UTI. Workup of
these risk factors includes bladder/bowel diaries, question-
naires, or behavioral and psychological screening.
Furthermore, it is advisable to perform uroflowmetry if dys-
functional voiding is suspected. It may be combined with
transcutaneous electromyography (EMG) of the perineal mus-
cles, particularly when uroflowmetry shows staccato voiding
to differentiate the underlying cause more precisely [51]. The
advantage of combining EMG with uroflowmetry is the abil-
ity to reveal intermittent contractions of the peri-urethral stri-
ated or levator ani muscles during voiding. This may aid in the
preparation of pelvic floor muscle training (biofeedback) or
neuromodulation with the help of urophysiotherapy [52].
Dysfunctional voiding can cause high intra-vesical pressure
and lack of complete bladder emptying predisposing to sec-
ondary VUR. A further and common risk factor is chronic
constipation which should be evaluated and treated promptly
in children with recurrent UTI with or without VUR [44].
Recommendation 11: Surgical and endoscopic
intervention should be considered in selected cases
on an individual basis (evidence quality: moderate;
recommendation: weak)
In children with high-grade VUR with recurrent infections
on prophylactic antibiotics or parental hesitancy to use
antibiotics, surgical intervention (e.g., endoscopic injec-
tions of bulking agents or ureteric reimplantation) may
be an alternative especially after the first year of life.
There is no consensus about the timing and type of sur-
gical correction [53].
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